SINT vs. GUTS, PSTV, WOK, NMTC, ZYXI, NEPH, MODD, TMDIF, ECOR, and RBOT
Should you be buying Sintx Technologies stock or one of its competitors? The main competitors of Sintx Technologies include Fractyl Health (GUTS), Plus Therapeutics (PSTV), WORK Medical Technology Group (WOK), NeuroOne Medical Technologies (NMTC), Zynex (ZYXI), Nephros (NEPH), Modular Medical (MODD), Titan Medical (TMDIF), electroCore (ECOR), and Vicarious Surgical (RBOT). These companies are all part of the "medical equipment" industry.
Sintx Technologies vs. Its Competitors
Sintx Technologies (NASDAQ:SINT) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.
Sintx Technologies presently has a consensus target price of $28.00, suggesting a potential upside of 543.68%. Fractyl Health has a consensus target price of $6.53, suggesting a potential upside of 540.52%. Given Sintx Technologies' higher probable upside, equities research analysts clearly believe Sintx Technologies is more favorable than Fractyl Health.
In the previous week, Sintx Technologies had 6 more articles in the media than Fractyl Health. MarketBeat recorded 7 mentions for Sintx Technologies and 1 mentions for Fractyl Health. Fractyl Health's average media sentiment score of 0.95 beat Sintx Technologies' score of 0.14 indicating that Fractyl Health is being referred to more favorably in the news media.
Sintx Technologies has a net margin of -674.05% compared to Fractyl Health's net margin of -73,864.52%. Sintx Technologies' return on equity of -256.59% beat Fractyl Health's return on equity.
18.4% of Sintx Technologies shares are held by institutional investors. 4.1% of Sintx Technologies shares are held by company insiders. Comparatively, 26.1% of Fractyl Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Sintx Technologies has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.
Sintx Technologies has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Fractyl Health has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.
Summary
Sintx Technologies beats Fractyl Health on 8 of the 15 factors compared between the two stocks.
Get Sintx Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SINT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sintx Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:SINT) was last updated on 9/14/2025 by MarketBeat.com Staff
Free SINT Stock Alerts